Full Press Release Details
Receives Notice of Patent Allowance in China for NASH Treatment
is out-licensed in China for NASH, projected to become $6.4 billion market by 2027
TIKVA, Israel, June 16, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline
of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Chinese National Intellectual
Property Administration has issued a Notice of Allowance for its patent titled "An A3 Adenosine Receptor Ligand For Use In Treating
Ectopic Fat Accumulation". This patent addresses the use of the A3 Adenosine Receptor (A3AR) ligand, the target receptor for Can-Fite's
drug platform technology, to reduce liver fat particularly in patients with non-alcoholic steatohepatitis (NASH).
expects to commence a Phase IIb study for its liver drug candidate Namodenoson in the treatment of NASH in Q3 2021 based on a successfully
concluded Phase IIa study in which Namodenoson was shown to reduce liver fat content and inhibit fibrosis.
has been out licensed for the treatment of NASH in China and is part of a deal worth up to $74.5 million in milestone payments plus double-digit
royalties. The treatment market for NASH in China is projected to reach $6.4 billion by 2027 driven by increasing rates of obesity, metabolic
syndrome, and diabetes.
we prepare to commence enrollment next quarter for our Phase IIb study of Namodenoson in the treatment of NASH, we are very pleased to
build our patent estate around our technology in this high-value indication. This latest NASH patent adds to those already issued in
the U.S., Europe, and South Korea," stated Can-Fite CEO Dr. Pnina Fishman.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that
is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's
lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate
COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form
of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan
Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration.
Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's
third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with
experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other
things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies
or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally
or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect,"
"intend," "plan," "may," "should" or "anticipate" or their negatives or other
variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current
matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S.
Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized
executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date
they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject
to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially
from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses
and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;
uncertainties of cash flows and inability to meet working capital needs; the impact of the COVID-19 pandemic; the initiation, timing,
progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance
our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory
approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization
and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations;
the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business
without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to
the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite's
filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities
values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation
to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.